Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cubist Hopes For A Blockbuster Antibiotic With In Acquisition Of Calixa

This article was originally published in The Pink Sheet Daily

Executive Summary

Cubist pays $92.5 million upfront for a private biotech and its lead programs, hoping to find a complementary product for Cubicin.

You may also be interested in...



Deals Of The Week: Allena/Althea, Almirall/Menarini, Bausch & Lomb/Ista

Earn-outs are more frequent in biotech M&A deals these days, but private investors also are becoming more savvy in terms of tracking earn-outs and which ones are more likely than others to pay off.

Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets

Cubist Pharmaceuticals laid out the regulatory plan for its novel broad-spectrum cephalosporin/tazobactam combination antibiotic CXA-201 during an R&D day Sept. 20, disclosing plans to go ahead with development of the drug in hospital-acquired and ventilator-associated pneumonia

Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets

Cubist Pharmaceuticals laid out the regulatory plan for its novel broad-spectrum cephalosporin/tazobactam combination antibiotic CXA-201 during an R&D day Sept. 20, disclosing plans to go ahead with development of the drug in hospital-acquired and ventilator-associated pneumonia

Related Content

Topics

UsernamePublicRestriction

Register

PS068867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel